8 The study has finished enrolling a total of 60 consecutive patients at four centers in the United States and is currently in the follow-up phase intended for 1 year.

The Auryon below-the-knee (BTK) study (Auryon BTK) is a multicenter, prospective, nonrandomized study designed to evaluate the effectiveness of the Auryon laser BTK in patients with limb ischemia (NCT05284240). 4 The limited available data on the use of the Auryon laser in treating infrapopliteal disease were one of the major factors in deciding to pursue the following study. In the EX-PAD-03 study, there were a total of 17 infrapopliteal arteries studied with no reported perforation, no distal embolization, and continued low TLR rates at 6 months. 7 The device is cleared to treat smaller infrapopliteal vessels, but little data are available about its effectiveness in plaque excision, adventitial injury, or long-term limb salvage in these small fibrocalcific vessels. 4,5 Additionally, given its limited penetration depth, it mostly spares the adventitia, 6 which is likely to be advantageous in lessening the chance of restenosis and TLR. 3 Data from the Auryon IDE study and the Auryon SCE study support the soft ablation concept and show low target lesion revascularization (TLR) rates at 6 months (< 5%) and 1 year (< 20%), respectively. 1,2 In larger vessels such as the femoropopliteal arteries, the device is a soft debulking tool with a reduction in plaque severity by about 33% but with a continued residual narrowing typically > 50%. The Auryon Atherectomy System (AngioDynamics, Inc.) has been shown to ablate calcified tissue but with low penetration depth.

Eximo laser atherectomy